H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Protagonist Therapeutics (PTGX) to $54 from $50 and keeps a Buy rating ...

NEWARK, CA / ACCESS Newswire / February 21, 2025 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended ...

Reports Q4 revenue $170.6M vs. $60M last year. “Protagonist is quickly approaching multiple late-stage transformational events expected in the ...

(formerly JNJ-2113) milestone earned in Q4 2024, received in January 2025PN-881, a potential best-in-class oral IL-17 receptor antagonist peptide nominated as a development candidate ...

BESREMi is a preferred, FDA-approved option for both symptomatic low- and high-risk polycythemia vera patients. In the polycythemia vera space, BESREMi faces competition from drugs like ruxolitinib, a ...

Opzelura is a treatment for nonsegmental vitiligo in patients 12 and older, making it the first and only cream in the U.S.

Today, a tribunal under the auspices of the International Chamber of Commerce (ICC) served a partial final award in a dispute ...

Medically reviewed by Gagandeep Brar, MD Bone marrow is the deep, interior portion of your bone. Your bone marrow, which has ...

Case Reports in the Journal of the American College of Cardiology Underscore the Critical Role of Blood Volume Analysis in ...

Just like any chronic health condition, polycythemia vera (PV) can have a negative impact on your everyday life. Research has ...

Basophilia at diagnosis of myeloproliferative neoplasms was associated with a more aggressive disease phenotype and poorer ...